UBC Faculty Research and Publications

Questioning the basis of approval for non-insulin glucose lowering drugs Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 100 considers the basis for the approval of non-insulin glucose lowering drugs. Conclusions: Widely prescribed glucose lowering drugs for people with type 2 diabetes have been approved in Canada without evidence that they reduce mortality or major morbidity. The best available evidence does not support Health Canada’s assertion that intensive glucose lowering in persons with type 2 diabetes “will contribute to the safety of subjects”. The current regulatory framework for glucose lowering drugs that bases benefit on lowering HbA1c and bases harms on not increasing specific cardiovascular outcomes requires rethinking.

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International